In an adult with elevated hemoglobin, high ferritin, and ALT at the upper limit of normal, what are the likely causes and recommended diagnostic work‑up and initial management?

Diagnostic Approach to Elevated Hemoglobin, High Ferritin, and Upper-Normal ALT

This pattern most likely represents secondary hyperferritinemia from metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), or chronic inflammation—not iron overload—and requires measurement of fasting transferrin saturation to confirm. 1

---

Immediate Diagnostic Steps

Order a fasting transferrin saturation (TS) immediately. This single test distinguishes true iron overload (TS ≥45%) from secondary hyperferritinemia (TS <45%), which accounts for over 90% of elevated ferritin cases. 1, 2

• If TS ≥45%: Suspect hereditary hemochromatosis or primary iron overload; proceed directly to HFE genetic testing for C282Y and H63D mutations. 1
• **If TS <45%:** Iron overload is excluded with >90% certainty; focus on secondary causes including NAFLD, metabolic syndrome, chronic alcohol use, inflammation, or liver disease. 1

Never diagnose iron overload based on ferritin alone—ferritin rises as an acute-phase reactant in inflammation, liver disease, malignancy, and tissue necrosis independent of actual iron stores. 1

---

Understanding the Hemoglobin Elevation

Hemoglobin of 169 g/L in an adult male is mildly elevated (normal range approximately 140–175 g/L), but does not meet criteria for polycythemia vera or significant erythrocytosis requiring urgent hematologic evaluation. 2, 3

Common causes of mild hemoglobin elevation include:

• Chronic hypoxia from smoking, sleep apnea, or chronic lung disease—the most frequent secondary cause in young adults. 3
• Relative erythrocytosis from dehydration or reduced plasma volume, often seen in obesity. 3
• Metabolic syndrome and obesity—43% of young adults with elevated hemoglobin in one cohort were obese. 3

Polycythemia vera is extremely rare in this context and would require hemoglobin >185 g/L in men plus JAK2 mutation testing. 3

---

Interpreting the Ferritin of 387 ng/mL

Ferritin of 387 ng/mL is elevated but falls well below the 1,000 µg/L threshold associated with organ damage risk (negative predictive value 94% for advanced liver fibrosis). 1

This level suggests:

• Secondary hyperferritinemia from inflammation, metabolic syndrome, NAFLD, or chronic alcohol use—not iron overload. 1
• Hepatocellular injury and insulin resistance if associated with metabolic syndrome/NAFLD, rather than true iron accumulation. 1
• Acute-phase reaction if concurrent infection, inflammation, or tissue injury is present. 1

Ferritin >1,000 µg/L with elevated liver enzymes predicts cirrhosis in 80% of C282Y homozygotes, but this patient's ferritin is below that threshold. 1

---

Evaluating the ALT of 40 IU/L

ALT of 40 IU/L is at the upper limit of normal (normal range for males 29–33 IU/L by modern standards, though commercial labs often use higher cutoffs). 4

This mild elevation suggests:

• Early NAFLD or metabolic syndrome—the most common cause when ferritin is elevated with normal transferrin saturation. 4
• Chronic alcohol consumption—even moderate intake (≥14–21 drinks/week in men) can elevate both ferritin and ALT. 4
• Medication-induced liver injury—review all prescription drugs, over-the-counter medications, and herbal supplements against the LiverTox® database. 4

ALT <5× upper limit of normal does not require urgent hepatology referral, but warrants systematic evaluation if persistent. 4

---

Complete Diagnostic Work-Up

Step 1: Confirm or exclude iron overload

• Fasting transferrin saturation (morning sample preferred). 1
• If TS ≥45%: Order HFE genetic testing (C282Y, H63D). 1
• If TS <45%: Proceed to evaluate secondary causes below. 1

Step 2: Assess for metabolic syndrome and NAFLD

• Fasting glucose or HbA1c to screen for diabetes/prediabetes. 4
• Fasting lipid panel to assess dyslipidemia. 4
• Blood pressure measurement and waist circumference to identify metabolic syndrome components. 4
• Abdominal ultrasound (sensitivity 84.8%, specificity 93.6% for moderate-severe hepatic steatosis) to confirm fatty liver. 4

Step 3: Screen for other liver diseases

• Viral hepatitis serologies (HBsAg, anti-HBc IgM, anti-HCV) to exclude chronic viral hepatitis. 4
• Autoimmune markers (ANA, anti-smooth muscle antibody, quantitative IgG) if autoimmune hepatitis is suspected. 4
• Detailed alcohol history using validated tools (AUDIT or AUDIT-C); intake ≥30 g/day in men mimics NAFLD. 4

Step 4: Evaluate for inflammatory causes

• C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) to detect occult inflammation. 1
• Complete blood count with differential to assess for anemia, polycythemia, or hematologic malignancy. 1

Step 5: Risk-stratify for advanced fibrosis

• Calculate FIB-4 score using age, ALT, AST, and platelet count. 4
  • FIB-4 <1.3 (<2.0 if age >65): Low risk for advanced fibrosis (negative predictive value ≥90%). 4
  • FIB-4 >2.67: High risk; refer to hepatology. 4

---

Initial Management Based on Most Likely Diagnosis

If NAFLD/metabolic syndrome is confirmed (TS <45%, fatty liver on ultrasound):

• Target 7–10% body weight loss through caloric restriction and a low-carbohydrate, low-fructose diet. 4
• Prescribe 150–300 minutes/week of moderate-intensity aerobic exercise plus resistance training ≥2 days/week. 4
• Treat metabolic comorbidities aggressively: statins for dyslipidemia, GLP-1 receptor agonists or SGLT2 inhibitors for diabetes, blood pressure control to <130/85 mmHg. 4
• Consider vitamin E 800 IU daily if biopsy-proven NASH (improves liver histology in 43% vs. 19% placebo). 4

If hereditary hemochromatosis is confirmed (TS ≥45%, C282Y homozygote):

• Initiate therapeutic phlebotomy without liver biopsy if ferritin <1,000 µg/L, normal liver enzymes, and age <40 years. 1
• Consider liver biopsy if ferritin >1,000 µg/L with elevated liver enzymes or platelet count <200,000/µL. 1
• Screen first-degree relatives with TS and ferritin. 1

If chronic alcohol use is identified:

• Recommend complete alcohol abstinence—even moderate consumption (≥14–21 drinks/week) exacerbates liver injury. 4
• Repeat liver enzymes in 2–4 weeks after cessation; expect normalization within 2–8 weeks if alcohol-induced. 4

---

Monitoring and Referral Thresholds

Repeat liver enzymes in 2–4 weeks to establish trend:

• If ALT normalizes or decreases: Continue monitoring every 4–8 weeks until stable. 4
• If ALT increases to ≥3× ULN (>90 IU/L): Intensify evaluation and repeat testing within 2–5 days. 4
• If ALT increases to >5× ULN (>145 IU/L): Urgent hepatology referral. 4

Refer to hepatology if:

• Ferritin >1,000 µg/L with elevated bilirubin or liver enzymes. 1
• Ferritin >10,000 µg/L regardless of other findings. 1
• TS ≥45% on repeat testing. 1
• ALT remains elevated ≥6 months without identified cause. 4
• FIB-4 score >2.67 indicating high risk for advanced fibrosis. 4

---

Critical Pitfalls to Avoid

• Do not assume iron overload without confirming TS ≥45%—over 90% of elevated ferritin cases are secondary. 1
• Do not overlook alcohol intake—quantitative assessment is essential, as moderate consumption mimics NAFLD. 4
• Do not ignore metabolic syndrome components—NAFLD is the most common cause of this pattern in adults with obesity, diabetes, or hypertension. 4
• Do not delay statin therapy if dyslipidemia is present—cardiovascular disease is the leading cause of death in NAFLD patients, outweighing liver-related mortality. 4
• Do not order HFE genetic testing when TS <45%—this leads to misdiagnosis and unnecessary phlebotomy. 1